Tumour growth delay was observed post treatment with 43‒66 MBq [177Lu]Lu-PSMA-617 (Fig. 5C and Table S3), but no survival improvement over the controls at any studied activity (p > 0.05, Fig. 5B; Table 1). This evidence concerns the gene FOLH1 and neoplasm.